FLT4 and melanoma: In melanoma, MDK activates mTOR via a similar signaling pathway (Figure 1), leading to an increased expression of vascular endothelial growth factor receptor 3 (VEGFR3) and the stimulation of lymphangiogenic signals, resulting in metastatic growth in lymph nodes and the lungs (63).